SIREN : 484758610
NEWMED is a French company founded 20 years ago, specialized in the sector Conseil en relations publiques et communication. Based in PARIS (75015), this company of category PME shows in 2017 a revenue of 955 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2017 | 2016 | 2015 |
|---|---|---|---|
| Revenue | 954 793 € | 627 874 € | 669 259 € |
| Net income | 196 261 € | 76 018 € | 77 683 € |
| EBITDA | 243 258 € | 192 234 € | 142 372 € |
| Net margin | 20.6% | 12.1% | 11.6% |
In 2017, NEWMED achieves revenue of 955 k€. Over the period 2015-2017, the company shows strong growth with a CAGR (compound annual growth rate) of +19.4%. Vs 2016, growth of +52% (628 k€ -> 955 k€). After deducting consumption (0 €), gross margin stands at 955 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 243 k€, representing 25.5% of revenue. Warning negative scissor effect: despite revenue change (+52%), EBITDA varies by +27%, reducing margin by 5.1 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 196 k€, i.e. 20.6% of revenue. This profit can be retained or distributed to shareholders.
954 793 €
954 793 €
243 258 €
280 433 €
196 261 €
25.5%
The debt ratio (= Financial debt / Equity x 100) stands at 3%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 76%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 16.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
3.074%
75.583%
16.674%
0.206
21.1%
In 2017, the debt ratio of NEWMED (3.07) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2017, the financial autonomy of NEWMED (75.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2017, the repayment capacity of NEWMED (0.21) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 476.45. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
476.446
0.0
In 2017, the liquidity ratio of NEWMED (476.45) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2017, the interest coverage of NEWMED (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 203 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 40 days. The gap of 163 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 138 days of revenue, i.e. 366 k€ to permanently finance. Over 2015-2017, WCR increased by +43%, requiring additional financing.
365 543 €
203 j
40 j
0 j
138 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 234 379€ to 1 131 919€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NEWMED with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil en relations publiques et communication
The revenue of NEWMED in 2017 is 955 k€.
Yes, NEWMED generated a net profit of 196 k€ in 2017.
The headquarters of NEWMED is located in PARIS (75015), in the department Paris.
The tax return of NEWMED is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NEWMED operates in the sector Conseil en relations publiques et communication (NAF code 70.21Z). See the 'Sector positioning' section above to compare the company with its competitors.